Lundbeck depression drug Brintellix clears EU hurdle
This article was originally published in Scrip
Executive Summary
Lundbeck's antidepressant Brintellix (vortioxetine) has been given a positive opinion by the committee that advises on drug approvals in the EU. The Committee for Medicinal Products for Human Use (CHMP) has recommended that the product be granted marketing authorization to treat major depressive episodes in adults.